Lonza: Two Distinct Activation Methods Yield Clinical-Scale Expansion of T Cells
Friday, May 31, 2024 01:15 PM - 01:45 PM
Room 212-214
Corporate Session
Speaker
In this presentation, we use two distinct methods to generate billions of γδ T cells from peripheral blood mononuclear cells (PBMCs). The first method uses zoledronic acid as the activating agent to induce the expansion of more than 1 x 109 Vδ2+ T cells within 14 days, starting from cryopreserved PBMCs. In the second approach, either αβ T cells are specifically depleted from PBMCs or γδ T cells are isolated via negative selection prior to anti-CD3 and anti-CD28 co-stimulation, and billions of γδ T cells are generated – including both Vδ1+ and Vδ2+ T cell subsets. Interestingly, the anti-CD3/anti-CD28 activation method supports high lentivirus transduction of the γδ T cells. The expanded γδ T cells exhibit innate cytotoxicity towards the K562 cell line and produce cytokines including IFN-γ and TNF-α. Collectively, these data indicate that both methods may be utilized to generate enough γδ T cells to support clinical applications.
- Chengkang Zhang, PhD, Associate Director R&D, Lonza Bioscience Solutions, United States
In this presentation, we use two distinct methods to generate billions of γδ T cells from peripheral blood mononuclear cells (PBMCs). The first method uses zoledronic acid as the activating agent to induce the expansion of more than 1 x 109 Vδ2+ T cells within 14 days, starting from cryopreserved PBMCs. In the second approach, either αβ T cells are specifically depleted from PBMCs or γδ T cells are isolated via negative selection prior to anti-CD3 and anti-CD28 co-stimulation, and billions of γδ T cells are generated – including both Vδ1+ and Vδ2+ T cell subsets. Interestingly, the anti-CD3/anti-CD28 activation method supports high lentivirus transduction of the γδ T cells. The expanded γδ T cells exhibit innate cytotoxicity towards the K562 cell line and produce cytokines including IFN-γ and TNF-α. Collectively, these data indicate that both methods may be utilized to generate enough γδ T cells to support clinical applications.
SPONSORED BY:
